ClinicalTrials.gg
CompletedNCT00043927Updated Aug 21, 2013

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

A Phase 3 interventional study of topotecan/cisplatin and etoposide/cisplatin in Small Cell Lung Cancer, sponsored by GlaxoSmithKline. Completed at 176 sites in 34 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing topotecan in Small Cell Lung Carcinoma — 2 open to participants now, 4 under way, 2 of them phase 3. Topotecan · Small Cell Lung Carcinoma.

Enrollment
Largest of 28
760 · median 44
Started
2001
with 1 other
Phase 3
7 of 29
1 open now
Registered
6th of 29
by date
Lead sponsor
7 of 29
GlaxoSmithKline

Among the 29 studies testing topotecan in Small Cell Lung Carcinoma, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 3, and was the 6th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 29 studies testing topotecan in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About topotecan

Topotecan: first FDA approval 1996 (HYCAMTIN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing topotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy. One treatment will use an investigational drug in combination with an FDA approved chemotherapy. The other treatment will use a combination of two FDA approved chemotherapy drugs.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Chemotherapy-naive
  • Small Cell Lung Cancer
  • SCLC
  • Extensive disease
  • ED
  • topotecan
  • Hycamtin
  • oral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (patient's written understanding of and agreement to participate in this study).
  • Patients with confirmed extensive small cell lung cancer (SCLC).
  • No prior chemotherapy within 5 years of the diagnosis of SCLC.
  • Presence of either measurable or non-measurable SCLC by X-ray or physical examination.
  • At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the patient).
  • At least 24 hours since prior radiotherapy. Patients who have received radiotherapy must have recovered from any reversible side effects, such as nausea and vomiting.
  • Laboratory criteria: Patients must have adequate bone marrow reserve and adequate kidney and liver function.

Exclusion criteria

Exclusion Criteria:

  • Symptoms of spreading of the disease to the brain that requires treatment with drugs called .
  • Any active infection.
  • Severe medical problems other than the diagnosis of SCLC, that would limit the ability of the patient to follow study guidelines or that would expose the patient to extreme risk.
  • Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or therapy for the treatment of SCLC.
  • Use of an investigational drug within 30 days before the first dose of study medication.
  • Women who are pregnant or lactating.
  • Patients of who refuse to practice an adequate form of .
  • Patients with clinical evidence of any stomach or intestinal (GI) condition.
  • Patients requiring treatment with the drug cyclosporin A.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
760 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival

Secondary outcomes

  1. response rates, response duration, time to progression, tolerability and patient-perceived disease status and well being for patients

07

Study locations

176 sites
  • GSK Clinical Trials Call Center
    Hoover, Alabama 35216, United States
  • GSK Clinical Trials Call Center
    Chula Vista, California 91911, United States
  • GSK Clinical Trials Call Center
    Fountain Valley, California 92708, United States
  • GSK Clinical Trials Call Center
    Greenbrae, California 94904, United States
  • GSK Clinical Trials Call Center
    Poway, California 92064, United States
  • GSK Clinical Trials Call Center
    Rancho Mirage, California 92270, United States
  • GSK Clinical Trials Call Center
    Sacramento, California 95816-5616, United States
  • GSK Clinical Trials Call Center
    San Diego, California 92102-8421, United States
  • GSK Clinical Trials Call Center
    San Diego, California 92121, United States
  • GSK Clinical Trials Call Center
    Soquel, California 95073, United States
  • GSK Clinical Trials Call Center
    Vista, California 92083, United States
  • GSK Clinical Trials Call Center
    Colorado Springs, Colorado 80909, United States
  • GSK Clinical Trials Call Center
    Norwich, Connecticut 06360, United States
  • GSK Clinical Trials Call Center
    Washington, District of Columbia 20307-5001, United States
  • GSK Clinical Trials Call Center
    Gainesville, Florida 32610, United States
  • GSK Clinical Trials Call Center
    Miami Shores, Florida 33138, United States
  • GSK Clinical Trials Call Center
    Ocala, Florida 34471, United States
  • GSK Clinical Trials Call Center
    Pensacola, Florida 32501, United States
  • GSK Clinical Trials Call Center
    Tarpon Springs, Florida 34689, United States
  • GSK Clinical Trials Call Center
    Atlanta, Georgia 30030, United States
  • GSK Clinical Trials Call Center
    Atlanta, Georgia 30308, United States
  • GSK Clinical Trials Call Center
    Atlanta, Georgia 30328, United States
  • GSK Clinical Trials Call Center
    Atlanta, Georgia 30335, United States
  • GSK Clinical Trials Call Center
    Augusta, Georgia 30912, United States
  • GSK Clinical Trials Call Center
    Cummings, Georgia 30040, United States
  • GSK Clinical Trials Call Center
    Decatur, Georgia 30033, United States
  • GSK Clinical Trials Call Center
    Aurora, Illinois 60506, United States
  • GSK Clinical Trials Call Center
    Chicago, Illinois 60612, United States
  • GSK Clinical Trials Call Center
    Chicago, Illinois 60637-1470, United States
  • GSK Clinical Trials Call Center
    Elk Grove Village, Illinois 60007, United States
  • GSK Clinical Trials Call Center
    Park Ridge, Illinois 60068, United States
  • GSK Clinical Trials Call Center
    Evansville, Indiana 47713, United States
  • GSK Clinical Trials Call Center
    South Bend, Indiana 46601, United States
  • GSK Clinical Trials Call Center
    New Orleans, Louisiana 70112, United States
  • GSK Clinical Trials Call Center
    Shreveport, Louisiana 71103, United States
  • GSK Clinical Trials Call Center
    Frederick, Maryland 21701, United States
  • GSK Clinical Trials Call Center
    Pittsfield, Massachusetts 01201, United States
  • GSK Clinical Trials Call Center
    Minneapolis, Minnesota 55404, United States
  • GSK Clinical Trials Call Center
    St. Louis, Missouri 63141, United States
  • GSK Clinical Trials Call Center
    Reno, Nevada 89502, United States
  • GSK Clinical Trials Call Center
    Voorhees, New Jersey 08043, United States
  • GSK Clinical Trials Call Center
    Albuquerque, New Mexico 87109, United States
  • GSK Clinical Trials Call Center
    Albany, New York 12208, United States
  • GSK Clinical Trials Call Center
    New York, New York 10021, United States
  • GSK Clinical Trials Call Center
    New York, New York 10032, United States
  • GSK Clinical Trials Call Center
    Rochester, New York 14623, United States
  • GSK Clinical Trials Call Center
    Valhalla, New York 10595, United States
  • GSK Clinical Trials Call Center
    Bismarck, North Dakota 58501, United States
  • GSK Clinical Trials Call Center
    Cleveland, Ohio 44106-5065, United States
  • GSK Clinical Trials Call Center
    Columbus, Ohio 43222, United States
  • GSK Clinical Trials Call Center
    Portland, Oregon 97232-2099, United States
  • GSK Clinical Trials Call Center
    Lemoyne, Pennsylvania 17043, United States
  • GSK Clinical Trials Call Center
    Limerick, Pennsylvania 19468, United States
  • GSK Clinical Trials Call Center
    Philadelphia, Pennsylvania 19140, United States
  • GSK Clinical Trials Call Center
    Columbia, South Carolina 29203, United States
  • GSK Clinical Trials Call Center
    Spartanburg, South Carolina 29303, United States
  • GSK Clinical Trials Call Center
    Memphis, Tennessee 38119, United States
  • GSK Clinical Trials Call Center
    Fort Worth, Texas 76104, United States
  • GSK Clinical Trials Call Center
    Houston, Texas 77060, United States
  • GSK Clinical Trials Call Center
    Abingdon, Virginia 24211, United States
  • GSK Clinical Trials Call Center
    Norfolk, Virginia 23502, United States
  • GSK Clinical Trials Call Center
    Olympia, Washington 98506, United States
  • GSK Clinical Trials Call Center
    Yakima, Washington 98902, United States
  • GSK Clinical Trials Call Center
    Morgantown, West Virginia 26506, United States
  • GSK Clinical Trials Call Center
    Madison, Wisconsin 53792, United States
  • GSK Clinical Trials Call Center
    Laramie, Wyoming 82070, United States
  • GSK Clinical Trials Call Center
    Vienna, A-1090, Austria
  • GSK Clinical Trials Call Center
    Vienna, A-1130, Austria
  • GSK Clinical Trials Call Center
    Vienna, A-1140, Austria
  • GSK Clinical Trials Call Center
    Charleroi, 6000, Belgium
  • GSK Clinical Trials Call Center
    Edegem, 2650, Belgium
  • GSK Clinical Trials Call Center
    Haine-Saint- Paul, 7100, Belgium
  • GSK Clinical Trials Call Center
    Leuven, 3000, Belgium
  • GSK Clinical Trials Call Center
    Liege, 4000, Belgium
  • GSK Clinical Trials Call Center
    Luxembourg, 1210, Belgium
  • GSK Clinical Trials Call Center
    Belo Horizonte, 30140-083, Brazil
  • GSK Clinical Trials Call Center
    Caxias do Sul, 95010-060, Brazil
  • GSK Clinical Trials Call Center
    Fortaleza, 60430-230, Brazil
  • GSK Clinical Trials Call Center
    Porto Alegre, 90020-090, Brazil
  • GSK Clinical Trials Call Center
    Porto Alegre, 90035-003, Brazil
  • GSK Clinical Trials Call Center
    Rio de Janeiro, 20230-130, Brazil
  • GSK Clinical Trials Call Center
    Salvador, 41920-000, Brazil
  • GSK Clinical Trials Call Center
    Sao Paulo, 04023-062, Brazil
  • GSK Clinical Trials Call Center
    Sao Paulo, 05403-900, Brazil
  • GSK Clinical Trials Call Center
    Bourgas, 8000, Bulgaria
  • GSK Clinical Trials Call Center
    Plovdiv, 4000, Bulgaria
  • GSK Clinical Trials Call Center
    Sofia, 1000/1527, Bulgaria
  • GSK Clinical Trials Call Center
    Sofia, 1156, Bulgaria
  • GSK Clinical Trials Call Center
    Varna, 9010, Bulgaria
  • GSK Clinical Trials Call Center
    Calgary, Alberta T2N 4N2, Canada
  • GSK Clinical Trials Call Center
    Edmonton, Alberta T6G 1E2, Canada
  • GSK Clinical Trials Call Center
    Winnipeg, Manitoba R3E 0V9, Canada
  • GSK Clinical Trials Call Center
    Sydney, Nova Scotia B1P 1P3, Canada
  • GSK Clinical Trials Call Center
    Newmarket, Ontario L3Y 2P9, Canada
  • GSK Clinical Trials Call Center
    Oshawa, Ontario L1G 2B9, Canada
  • GSK Clinical Trials Call Center
    Ottawa, Ontario K1H 1C4, Canada
  • GSK Clinical Trials Call Center
    Peterborough, Ontario K9H 7B6, Canada
  • GSK Clinical Trials Call Center
    Sault Sainte Marie, Ontario P6B 1Y5, Canada
  • GSK Clinical Trials Call Center
    Thunder Bay, Ontario P7B 6V4, Canada
  • GSK Clinical Trials Call Center
    Toronto, Ontario M5G 2M9, Canada

Showing the first 100 of 176 sites across 34 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001 and a primary completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2002
First posted
Aug 16, 2002
Start
Apr 2001
Primary completionActual
Jan 2004
Last update
Aug 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00043927
Lead sponsor
GlaxoSmithKline
First posted
Aug 16, 2002
Start date
Apr 2001
Primary completion
Jan 2004
Last update
Aug 21, 2013

Study contacts

GSK Clinical Trial, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Topotecan · Cisplatin

Start the discussion